Updated on 23 July 2012
The research on BDM-E was conducted under retinal disease specialist Professor Jennifer Wilkinson-Berka from Monash University, a senior research fellow of the National Health and Medical Research Council (NHMRC) of Australia, and Associate Professor Erica Fletcher from The University of Melbourne.
The encouraging results add further momentum to BioDiem's plan to outlicense the BDM-E technology. "These results contribute to the strong and growing preclinical evidence showing BDM-E's positive effect in models of eye disease, and will help progress out-licensing opportunities for the drug," said BioDiem Chief Executive Officer Julie Phillips.
Get direct access to more such reports. Subscribe to BioSpectrum Bureau 
Survey Box
Subscribe to BioSpectrum Asia digital mag at an attractive price of US $49.99 a year
(Includes all 24 regular & special issues @ fortnightly frequency)
Send this article by email
Australia
China
India
Japan
Korea
Malaysia
New Zealand 
Singapore
Taiwan
Thailand
